Model for End-Stage Liver Disease (MELD) and allocation of donor livers

被引:2165
|
作者
Wiesner, R
Edwards, E
Freeman, R
Harper, A
Kim, R
Kamath, P
Kremers, W
Lake, J
Howard, T
Merion, RM
Wolfe, RA
Krom, R
机构
[1] Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA
[2] United Network Organ Sharing, Richmond, VA USA
[3] Tufts Univ New England Med Ctr, Boston, MA 02111 USA
[4] Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA
[5] Suburban Surg Associates, St Louis, MO USA
[6] Sci Registry Transplant recipients, Ann Arbor, MI USA
关键词
D O I
10.1053/gast.2003.50016
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: A consensus has been reached that liver donor allocation should be based primarily on liver disease severity and that waiting time should not be a major determining factor. Our aim was to assess the capability of the Model for End-Stage Liver Disease (MELD) score to correctly rank potential liver recipients according to their severity of liver disease and mortality risk on the OPTN liver waiting list. Methods: The MELD model predicts liver disease severity based on serum creatinine, serum total bilirubin, and INR and has been shown to be useful in predicting mortality in patients with compensated and decompensated cirrhosis. In this study, we prospectively applied the MELD score to estimate 3-month mortality to 3437 adult liver transplant candidates with chronic liver disease who were added to the OPTN waiting list at 2A or 213 status between November, 1999, and December, 2001. Results: In this study cohort with chronic liver disease, 412 (12%) died during the 3-month follow-up period. Waiting list mortality increased directly in proportion to the listing MELD score. Patients having a MELD score <9 experienced a 1.9% mortality, whereas patients having a MELD score greater than or equal to40 had a mortality rate of 71.3%. Using the c-statistic with 3-month mortality as the end point, the area under the receiver operating characteristic (ROC) curve for the MELD score was 0.83 compared with 0.76 for the Child-Turcotte-Pugh (CTP) score (P < 0.001). Conclusions: These data suggest that the MELD score is able to accurately predict 3-month mortality among patients with chronic liver disease on the liver waiting list and can be applied for allocation of donor livers.
引用
下载
收藏
页码:91 / 96
页数:6
相关论文
共 50 条
  • [11] Model for end-stage liver disease (MELD) exception for portopulmonary hypertension
    Krowka, Michael J.
    Fallon, Michael B.
    Mulligan, David C.
    Gish, Robert G.
    LIVER TRANSPLANTATION, 2006, 12 (12) : S114 - S116
  • [12] Model for end-stage liver disease (MELD) exception for cystic fibrosis
    Horslen, Simon
    Sweet, Stuart
    Gish, Robert G.
    Shepherd, Ross
    LIVER TRANSPLANTATION, 2006, 12 (12) : S98 - S99
  • [13] Model for end-stage liver disease (MELD) exception for primary hyperoxaluria
    Horslen, Simon
    Gish, Robert G.
    McDonald, Ruth
    LIVER TRANSPLANTATION, 2006, 12 (12) : S117 - S118
  • [14] Model for end-stage liver disease (MELD) exception for severe pruritus
    Washburn, W. Kenneth
    Gish, Robert G.
    LIVER TRANSPLANTATION, 2006, 12 (12) : S119 - S119
  • [15] Model for end-stage liver disease (MELD) exception for bacterial cholangitis
    Gores, Gregory J.
    Gish, Robert G.
    Shrestha, Roshan
    Wiesner, Russell H.
    LIVER TRANSPLANTATION, 2006, 12 (12) : S91 - S92
  • [16] Model for end-stage liver disease (MELD) exception for hepatopulmonary syndrome
    Fallon, Michael B.
    Mulligan, David C.
    Gish, Robert G.
    Krowka, Michael J.
    LIVER TRANSPLANTATION, 2006, 12 (12) : S105 - S107
  • [17] Graphical display of Model for End-stage Liver Disease (MELD) score
    Chiarla, Carlo
    Giovannini, Ivo
    Ardito, Francesco
    Vellone, Maria
    Giuliante, Felice
    LIVER INTERNATIONAL, 2012, 32 (08) : 1322 - 1323
  • [18] Model for end-stage liver disease (MELD) exception for hepatic encephalopathy
    Ham, John
    Gish, Robert G.
    Mullen, Kevin
    LIVER TRANSPLANTATION, 2006, 12 (12) : S102 - S104
  • [19] Could tenofovir modify the model end-stage liver disease (MELD) score in patients with end-stage liver disease eligible for liver transplantation?
    Bruno, Raffaele
    Sacchi, Paolo
    Filice, Gaetano
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2007, 45 (01) : 123 - 123
  • [20] Impact of model for end-stage liver disease (MELD) and delta MELD (MELD) on outcome following liver transplantation.
    Bhati, CS
    Tamijmarane, A
    Gunson, B
    Mayer, DF
    Buckels, JAC
    Mirza, DF
    Wigmore, SJ
    Brahmall, SR
    LIVER TRANSPLANTATION, 2006, 12 (05) : C80 - C80